Jennifer Cook
Nurse Practitioner · Charlotte, NCNPI 1023671070
Payments from drug & device makers
Across 173 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$763
- Novo Nordisk$305
- Johnson & Johnson$238
- Lilly USA, LLC$178
- Boehringer Ingelheim$160
- AstraZeneca$151
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,873100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $763 |
| Novo Nordisk | 21 | $305 |
| Johnson & Johnson | 13 | $238 |
| Lilly USA, LLC | 11 | $178 |
| Boehringer Ingelheim | 10 | $160 |
| AstraZeneca | 10 | $151 |
| Otsuka America Pharmaceutical, Inc. | 7 | $134 |
| Mylan Specialty L.p. | 7 | $130 |
| Bayer | 7 | $125 |
| Vanda Pharmaceuticals Inc. | 5 | $108 |
| Astellas Pharma US Inc | 6 | $97 |
| Amarin Pharma, Inc. | 5 | $73 |
| Pfizer | 3 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $41 |
| Dexcom, Inc. | 3 | $40 |
| Amgen | 3 | $35 |
| Novartis | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Exact Sciences | 2 | $28 |
| Eisai Inc. | 2 | $24 |
| GSK | 2 | $24 |
| Inari Medical, Inc. | 1 | $21 |
| Nalu Medical, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$2,873 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $38,293 |
| FarxigaDapagliflozin Propanediol | 45 | $35,771 |
| JardianceEmpagliflozin | 36 | $25,698 |
| JanuviaSitagliptin Phosphate | 27 | $19,532 |
| RexultiBrexpiprazole | 13 | $17,565 |
| LinzessLinaclotide | 13 | $10,955 |
| TradjentaLinagliptin | 15 | $10,082 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,151 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $9,006 |
| EliquisApixaban | 13 | $8,795 |
| MyrbetriqMirabegron | 13 | $5,492 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,277 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $3,075 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,874 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $151 | $47,35170 claims |
| Novo NordiskOzempic | $305 | $38,29337 claims |
| Boehringer IngelheimJardiance, Tradjenta | $160 | $35,78051 claims |
| MerckJanuvia | $19 | $19,53227 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $134 | $17,56513 claims |
| AbbVieLinzess | $763 | $10,95513 claims |
| PfizerEliquis | $43 | $8,79513 claims |
| Astellas Pharma US IncMyrbetriq | $97 | $5,49213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Charlotte
- Mary DilorenzoCharlotte$71K
- Dennis TaylorCharlotte$39K
- Geovanna DeeseCharlotte$26K
- Melissa TharpeCharlotte$24K
- Marie MooreCharlotte$21K
- Natasha LaunganiCharlotte$18K
- Vicki MortonCharlotte$18K
- Courtney CarrCharlotte$18K
- Travis ShipeCharlotte$17K
- Kelly XiongCharlotte$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.